Solving the off-target effects of CRISPR/Cas9
We spoke to Mark Behlke, the chief scientific officer of Integrated DNA Technologies (IA, USA), about the current limitations of CRISPR/Cas9 techniques and the potential of the novel HiFI Cas9 enzyme to resolve these limitations, as shown in a sickle cell disease-causing mutation.
